| Bristol-Myers Squibb SA - Lenalidomid BMS 2,5 mg, Hartkapseln | | 68490 | | 01 | | Lenalidomid BMS 2,5 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 14.06.2021 | | |
| | Composition | | lenalidomidum 2.5 mg, lactosum 73.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.2 mg, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (flavum), E 132, Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Active Agent | Dose |
|---|
| Lenalidomidum | 2.5 mg |
| | BAG: Active Agent | Dose |
|---|
| Lenalidomidum | 2.5 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| | | | | | | | | | | | | | | | | | | color. | | | | color. | | | | color. | | Gelatina | | Kapselhülle | | | | | | | | Drucktinte | | | 73.5 mg | | | | | | | | | | | Propylenglycol | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 21 | 689.23 | 766.00 | A | SL | No |
|
|
